Core Insights - U.S. stock futures showed mixed signals as investors awaited key economic indicators and Federal Reserve Chair Jerome Powell's speech, following a strong session where major indices reached record highs driven by AI optimism and anticipated rate cuts [1][2]. Premarket Trading Activity and Futures Movements - Nasdaq 100 futures rose by 0.04%, while S&P 500 futures were up 0.01% and Dow futures increased by 0.07%, indicating a cautious sentiment among traders ahead of economic data releases [2]. Current Performance of Major Market Indexes - On Monday, the Nasdaq Composite rose 0.70% to close at 22,788.98, the S&P 500 climbed 0.44% to 6,693.75, and the Dow Jones Industrial Average increased by 0.14% to finish at 46,381.54, all achieving new closing highs [4]. Important Upcoming Market Events - Key events include Jerome Powell's speech on monetary policy and the release of flash PMI data, with a focus on the upcoming PCE price index, which is crucial for future policy decisions [5][6]. Major Stock News and Developments - Nvidia's shares surged approximately 4% following a $100 billion deal with OpenAI, while Apple Inc. saw a 4.3% increase due to strong iPhone 17 demand. Oracle Corp. climbed 6.3% after appointing new co-CEOs, and Boeing advanced 2.5% amid U.S.-China aircraft order negotiations [8][10]. - Pfizer announced its acquisition of Metsera for $4.9 billion, causing Metsera's stock to soar over 60%. Other notable movements included Kenvue rebounding 5.7%, Plug Power rising 6.65%, and Firefly Aerospace slumping 11% after financial results [11].

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Core Viewpoint - Kenvue shares experienced a recovery of over 5% in premarket trading after hitting a record low, following comments made by US President Donald Trump regarding the company's popular pain relief product [1] Group 1 - Kenvue's stock price rose more than 5% in premarket trading on Tuesday [1] - The increase in share price comes after the company reached a record low in the previous session [1] - US President Donald Trump's remarks linked to Kenvue's pain relief product contributed to the recovery in stock price [1]

Group 1 - The core viewpoint is that independent scientific evidence indicates acetaminophen does not cause autism, as stated by a Kenvue spokesperson [1]

Group 1: Technology and AI Investments - Nvidia plans to invest up to $100 billion in Microsoft-backed OpenAI to develop new AI data centers, highlighting its significant role in AI infrastructure [2] - Alibaba has launched its open-source large language model, Qwen3-Omni, which integrates text, image, audio, and video capabilities into a single model [3] Group 2: Aerospace Industry Developments - The U.S. and China are nearing a substantial Boeing aircraft order, potentially involving up to 500 aircraft, which could be Boeing's largest deal with China since 2017 [4] Group 3: Pharmaceutical Industry Concerns - The Trump administration has raised concerns about the use of Tylenol during pregnancy, suggesting a potential link to autism, although this claim lacks scientific backing [5][6] - Kenvue, the maker of Tylenol, maintains that the medication is safe, with estimates indicating it accounts for about 10% of the company's total revenue [7] - The warning regarding Tylenol could lead to increased lawsuits against Kenvue, which has faced around 500 lawsuits since 2022, although previous claims were dismissed due to insufficient evidence [8]

此外，英国卫生大臣韦斯.斯特里廷告诉英国患者，不要理会唐纳德.特朗普关于孕妇避免服用泰诺(在英 国称为扑热息痛)的呼吁，这是英国部长公开批评美国总统的罕见例子。 特朗普政府的警告可能导致针对Kenvue的诉讼增加，指控产前接触泰诺导致自闭症。 2023年从强生(JNJ.US)分拆出来的Kenvue自2022年以来已面临约500起此类诉讼。这些诉讼已在2023年 被驳回，当时一名联邦法官裁定无充分证据表明泰诺会导致自闭症。 花旗分析师表示，他们预计特朗普政府的警告对Kenvue构成的司法风险有限，"但负面新闻可能对泰诺 的销售产生一定影响"。虽然早期一些研究指出孕期服用泰诺与自闭症存在相关性，但2024年一项广泛 研究分析了瑞典近250万名儿童跨越25年的数据，最终结论两者间不存在关联。 智通财经APP注意到，泰诺生产商Kenvue(KVUE.US)股价周二盘前交易中上涨6%，该股昨日下跌 7.47%，此前特朗普政府警告孕期使用该公司生产的止痛药泰诺可能与自闭症有关。 值得注意的是，过去六个月因泰诺涉嫌与自闭症存在关联的指控频现，该股已累计下跌超四分之一。截 至发稿，Kenvue盘前涨6.01%，报17.99美 ...

Group 1: Kenvue and Acetaminophen Controversy - Kenvue's stock rebounded by 6% in premarket trading after a 7.5% drop due to concerns raised by the Trump administration regarding acetaminophen use during pregnancy [3][4]. - The company, a spinoff of Johnson & Johnson, defends acetaminophen as the safest pain reliever for pregnant women, citing rigorous research and endorsements from medical professionals [5]. - The FDA has issued a strong recommendation against the use of acetaminophen during pregnancy, which may lead to potential lawsuits for Kenvue [6]. Group 2: Boeing's Major Order - Boeing received an order from Uzbekistan Airways for up to 22 787 Dreamliner jets, marking the airline's largest-ever purchase [7]. - The order includes 14 787-9 airplanes with options for eight additional jets, aimed at modernizing Uzbekistan Airways' fleet and expanding international routes [8]. Group 3: Meta's New Dating Features - Meta Platforms introduced new features in its Facebook Dating service to combat "swipe fatigue," including a dating assistant chatbot and a "Meet Cute" feature for surprise matches [10][11]. - The introduction of these features negatively impacted shares of rival dating services, with Match Group and Bumble seeing declines of 5.4% and 3% respectively [12].

Kenvue stock rallied on Tuesday off a record low, after a White House press conference didn't offer fresh evidence that could be used by plaintiffs to sue the maker of Tylenol for its alleged link to ... ...

Group 1 - Kenvue's stock experienced a decline of approximately 7.5% yesterday, followed by a pre-market rebound of over 6%, reaching $18.02 [1] - President Trump warned pregnant women against using Tylenol, citing a potential link between acetaminophen and autism, despite the lack of widely accepted scientific evidence [1] - Kenvue issued a statement asserting confidence in independent and reliable scientific evidence that acetaminophen does not cause autism, strongly opposing contrary claims [1]

Core Insights - Kenvue, the maker of Tylenol, experienced a rise in stock prices during European trading despite controversial comments made by U.S. President Donald Trump linking its pain medication to autism risk during pregnancy [1] Company Summary - Kenvue's stock performance indicates resilience in the face of negative publicity, suggesting potential investor confidence in the company's long-term prospects [1] Industry Summary - The incident highlights ongoing concerns regarding the safety of over-the-counter medications during pregnancy, which may impact consumer perception and regulatory scrutiny in the pharmaceutical industry [1]